View Older Stories View More Recent Stories

Oct 18, 2024 05:50AM Merck's (MRK) MK-1654 Significantly Reduced Incidence of RSV Disease and Hospitalization in Healthy Preterm and Full-term Infants
Oct 17, 2024 06:00PM Merck’s Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus (RSV) Preventative Monoclonal Antibody, Significantly Reduced Incidence of RSV Disease and Hospitalization in Healthy Pr
Oct 16, 2024 06:45AM Merck's (MRK) CAPVAXIVE Demonstrates Positive Immune Responses in Adults with Increased Risk for Pneumococcal Disease
Oct 16, 2024 06:45AM Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Adults with Increased Risk for Pneumococcal Disease
Oct 14, 2024 08:02AM Exelixis (EXEL) and Merck (MRK) Sign Clinical Development Collaboration to Evaluate Investigational Zanzalintinib in Combination with KEYTRUDA
Oct 14, 2024 08:00AM Exelixis and Merck Sign Clinical Development Collaboration to Evaluate Investigational Zanzalintinib in Combination with KEYTRUDA® (pembrolizumab) in Head and Neck Cancer and in Combination with WELI
Oct 9, 2024 08:01AM MilliporeSigma Opens New €290 Million Biosafety Testing Facility in Rockville, Maryland, USA
Oct 9, 2024 06:45AM New Data to be Presented at IDWeek 2024 Reinforce Merck’s Broad and Diverse Vaccines and Infectious Disease Pipeline and Portfolio
Oct 8, 2024 06:45AM Merck's (MRK) KEYTRUDA Met Primary Endpoint of Event-Free Survival (EFS) as Perioperative Treatment Regimen in Patients With Resected, Locally Advanced Head and Neck Squamous Cell Carcinoma
Oct 8, 2024 06:45AM Merck’s KEYTRUDA® (pembrolizumab) Met Primary Endpoint of Event-Free Survival (EFS) as Perioperative Treatment Regimen in Patients With Resected, Locally Advanced Head and Neck Squamous Cell Carcin
Oct 1, 2024 06:46AM Merck (MRK) Completes Acquisition of CN201 from Curon Biopharmaceutical
Oct 1, 2024 06:45AM Merck Completes Acquisition of Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical
Oct 1, 2024 06:30AM Merck to Hold Third-Quarter 2024 Sales and Earnings Conference Call Oct. 31
Sep 26, 2024 06:46AM Merck (MRK) to Present New Long-Term Data for Tulisokibart
Sep 26, 2024 06:45AM Merck to Present New Long-Term Data for Tulisokibart (MK-7240), an Investigational Anti-TL1A Monoclonal Antibody, in Inflammatory Bowel Disease at UEG Week 2024
Sep 25, 2024 06:45AM Merck (MRK) Provides Update on Phase 3 KEYFORM-007 Trial of Investigational Fixed-Dose Combination of Favezelimab and Pembrolizumab
Sep 25, 2024 06:45AM Merck Provides Update on Phase 3 KEYFORM-007 Trial Evaluating Investigational Fixed-Dose Combination of Favezelimab and Pembrolizumab for Patients With Previously Treated PD-L1 Positive Microsatellite
Sep 25, 2024 06:30AM Merck's (MRK) KEYTRUDA Receives New Approvals in Japan for Certain Patients With Non-Small Cell Lung Carcinoma
Sep 25, 2024 06:30AM Merck’s KEYTRUDA® (pembrolizumab) Receives New Approvals in Japan for Certain Patients With Non-Small Cell Lung Carcinoma (NSCLC) and Radically Unresectable Urothelial Carcinoma
Sep 24, 2024 08:06AM Merck Animal Health (MRK) Announces Expansion of NOBIVAC NXT Platform
Sep 24, 2024 08:06AM Merck Animal Health Announces Expansion of NOBIVAC® NXT Platform with the First and Only RNA-Particle Technology Vaccine for Feline Leukemia Virus
Sep 20, 2024 09:00AM How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs
Sep 20, 2024 07:30AM Merck (MRK) Receives Positive EU CHMP Opinions for KEYTRUDA Regimens as Treatment for Patients With Two Types of Gynecologic Cancers
Sep 20, 2024 07:30AM Merck Receives Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Regimens as Treatment for Patients With Two Types of Gynecologic Cancers
Sep 18, 2024 06:46AM Merck (MRK) Announces FDA Approval of KEYTRUDA Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Advanced or Metastatic MPM
Sep 18, 2024 06:45AM FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesoth
Sep 17, 2024 06:00AM Patritumab Deruxtecan Demonstrated Statistically Significant Improvement in Progression-Free Survival Versus Doublet Chemotherapy in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small
Sep 16, 2024 06:16AM Merck (MRK) Reports Ten-Year Data for KEYTRUDA Demonstrated Sustained Overall Survival Benefit Versus Ipilimumab in Advanced Melanoma
Sep 15, 2024 10:30AM KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as Single Agent After Surgery Reduced Risk of Death by More Than One-Third (34%) Versus Neoadjuvant Chemotherapy in High-Risk
Sep 15, 2024 08:45AM Ten-Year Data for Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Sustained Overall Survival Benefit Versus Ipilimumab in Advanced Melanoma
Sep 14, 2024 10:35AM KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination With Transarterial Chemoembolization Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unre
Sep 14, 2024 10:30AM Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Reduced Risk of Death by 33% Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
Sep 14, 2024 03:15AM KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Significantly Improved Overall Survival (OS) Versus Trastuzumab and Chemotherapy Alone in First-Line Treatment of Patients With HER2-Positi
Sep 11, 2024 06:45AM Merck to Participate in the Bank of America 2024 Global Healthcare Conference
Sep 11, 2024 06:30AM Merck (MRK) Reports Positive Top-line Results from Phase 3 Trial Evaluating Efficacy and Safety of GARDASIL 9
Sep 11, 2024 06:30AM Merck Announces Positive Top-line Results from Phase 3 Trial Evaluating Efficacy and Safety of GARDASIL®9 in Japanese Males
Sep 10, 2024 08:00AM MilliporeSigma Launches Single-Use Reactor Designed to Accelerate Antibody Drug Conjugate Manufacturing
Sep 7, 2024 11:30AM Ifinatamab Deruxtecan Continues to Demonstrate Promising Objective Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial
Sep 4, 2024 06:45AM Merck to Present Survival Data and New Research on 10 Investigational or Approved Medicines at ESMO Congress 2024
Sep 4, 2024 06:40AM Merck (MRK) and EyeBio Initiate Phase 2b/3 Trial for Restoret
Sep 4, 2024 06:40AM Merck and EyeBio Announce Initiation of Phase 2b/3 Clinical Trial for Restoret™ for the Treatment of Diabetic Macular Edema
Sep 3, 2024 08:00AM MilliporeSigma Receives Industry First EXCiPACT Certification for Cell Culture Media Manufacturing
Sep 3, 2024 06:46AM Merck (MRK) Announces EU Approval of KEYTRUDA Plus Padcev as First-Line Treatment of Unresectable or Metastatic Urothelial Carcinoma in Adults
Sep 3, 2024 06:45AM European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First-Line Treatment of Unresectable or Metastatic Urothelial Carcinoma in Adults
Aug 29, 2024 06:45AM Merck to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Aug 29, 2024 06:30AM Merck (MRK) Provides Update on Phase 3 KEYNOTE-867 and KEYNOTE-630 Trials
Aug 29, 2024 06:30AM Merck Provides Update on Phase 3 KEYNOTE-867 and KEYNOTE-630 Trials
Aug 27, 2024 06:47AM Merck (MRK) Announces Phase 3 Trial Initiation for Bomedemstat
Aug 27, 2024 06:45AM Merck Announces Phase 3 Trial Initiation for Bomedemstat, an Investigational Candidate for the Treatment of Certain Patients With Essential Thrombocythemia
Aug 26, 2024 06:47AM Merck (MRK) Receives European Commission Approval for WINREVAIR (sotatercept)
View More Recent Stories View Older Stories